7 citations
,
March 2023 in “Pharmacy” In this study, a community pharmacy-based intervention in Serbia was associated with significant improvements in clinical symptoms for patients with post-COVID syndrome.
6 citations
,
August 2024 in “Viruses” This review reported that despite identifying over 200 symptoms associated with long COVID, significant gaps and controversies remain in understanding its diagnosis, pathophysiology, risk factors, and the impact of viral strains and vaccination.
6 citations
,
December 2023 in “Lancet. Infectious diseases/The Lancet. Infectious diseases” This study found that treatment with the synbiotic SIM01 significantly alleviated multiple symptoms of post-acute COVID-19 syndrome compared to placebo, suggesting potential management benefits through gut microbiome modulation.
6 citations
,
August 2023 in “Fertility and Sterility” This review details the 2023 International Guideline update for assessing and managing polycystic ovary syndrome, which provides evidence-based recommendations to improve care and patient outcomes but notes the remaining low to moderate quality of evidence.
5 citations
,
December 2024 in “Pharmaceutics” This review discusses the potential of using nanomaterial-based drug delivery systems to improve the treatment of polycystic ovary syndrome but reports no new clinical results, highlighting future research directions.
3 citations
,
July 2024 in “Biomolecules” This paper explores how melatonin interacts with various magnetic fields, noting that it can enhance certain positive health effects or inhibit destructive processes, but may also exacerbate conditions like multiple sclerosis by intensifying inflammation.
2 citations
,
September 2025 in “Food Production Processing and Nutrition” This review highlights capsaicin's chemical properties, natural sources, and its potential benefits such as antioxidant, anti-inflammatory, and analgesic effects, while also noting its challenges in food applications regarding dosage, taste perception, and regulatory compliance.
2 citations
,
May 2023 in “International Journal of Molecular Sciences” This review discusses current knowledge about the TRPV3 ion channel's role in skin functions and diseases, highlighting its potential as a therapeutic target for pain and itch, though suitable ligands are limited.
1 citations
,
August 2025 in “The Egyptian Journal of Internal Medicine” This paper reviews obesity diagnosis and screening methods, emphasizing BMI's practicality in low- and middle-income countries, but provides no new clinical results.
1 citations
,
February 2024 in “Pharmaceutics” This review highlights recent developments in nanovesicular carriers for enhancing molecule delivery into and across the skin, focusing on the design and evolution of phospholipid and non-phospholipid systems used in cosmetics and treating various skin conditions.
1 citations
,
May 2023 in “European Journal of Human Genetics” This study observed that numerical chromosomal aberrations were more common in men with severe male factor infertility and azoospermia compared to those with other sperm quality issues, while chromosomal translocations were significantly associated with oligoasthenozoospermia, highlighting important genetic counseling considerations.
April 2026 in “Metabolites” This narrative review explores the strong association between various chronic inflammatory skin diseases and metabolic syndrome, emphasizing shared inflammatory pathways and chemokine involvement, though the precise molecular connections remain partially understood.
March 2026 in “Journal for ImmunoTherapy of Cancer” This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.
September 2025 in “Wound Repair and Regeneration” This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.
January 2025 in “Open Medicine” This review discusses the connection between acne and metabolic syndrome, noting shared pathogenic mechanisms and suggesting integrated management strategies without presenting new clinical results.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” This research paper reviews the mechanisms and management of non-biologic immunosuppressive drugs used in dermatology, highlighting their safety profiles and handling during pregnancy, breastfeeding, and vaccination, but does not report specific results on these aspects.
September 2023 in “F&S reports” This review examines theories linking PCOS with psychiatric disorders, highlighting dietary interventions like probiotics and nutrients as possible improvements, but reports no new clinical findings and calls for more research.
This article discusses the impact of hyperandrogenism in polycystic ovary syndrome on women's physical and mental health, but it reports no new experimental findings.
Topical finasteride may better target hair follicles without significant benefits over oral form.
January 2026 in “International Journal of Innovative Technologies in Social Science” This review synthesizes information on isotretinoin’s systemic toxicity, emphasizing that its adverse effects, including mucocutaneous, hepatic, and musculoskeletal reactions, primarily reflect its pharmacodynamic actions and are generally manageable with individualized dosing and monitoring, though its teratogenicity remains a significant safety concern.
21 citations
,
January 2022 in “Pharmaceutics” This systematic review investigated colchicine as a potential treatment for various skin conditions, finding that most studies reported generally positive clinical outcomes when used alone or with other drugs, despite some variability in results.
17 citations
,
August 2014 in “American Journal of Physiology-gastrointestinal and Liver Physiology” This study found that finasteride significantly improved motor, EEG, and cellular changes in a rat model of thioacetamide-induced hepatic encephalopathy and prevented the development of hepatic coma.
January 2025 in “Case Reports in Gastrointestinal Medicine” This case report presented by the authors provides the first evidence of severe liver failure associated with the use of topical minoxidil, emphasizing the potential for hepatotoxicity even from drugs with minimal systemic absorption.
January 2025 in “Investigative and Clinical Urology” This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.
56 citations
,
August 1981 in “Journal of The American Academy of Dermatology” Minoxidil helps hair regrowth in alopecia areata safely.
4 citations
,
May 2025 in “npj Parkinson s Disease” This study identified peripheral myeloid cells as the earliest dysregulated immune cells in PINK1 KO mice with Parkinson’s-like symptoms following intestinal infections, suggesting that PINK1 regulates gut immune functions linked to early Parkinson’s disease mechanisms.
363 citations
,
May 2006 in “Current Opinion in Psychiatry” This review highlights that medical complications, notably in anorexia nervosa, are common and often serious in patients with eating disorders, affecting multiple organ systems.
17 citations
,
January 2013 in “Indian Journal of Pharmacology” This case report highlights an interest in exploring the relationship between serum levels of sodium valproate and hair loss, though no case reports currently establish this link.
1 citations
,
May 2008 in “Toxicon” This study found that BOTOX doses of 75–100 U effectively reduce postvoiding residual urine and detrusor pressure in patients with detrusor sphincter dyssynergia.